Merrimack Pharma Reports Q4 EPS -$0.09 Vs Est -$0.19; Expects to Start Clinical Trials of MM-398, MM-141 in Front-Line Pancreatic Cancer in 2015; Expects Completion of NDA Submission to FDA for MM-398 in Late 1Q/Early 2Q 2015